Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

12 trials in Phase 3/4

Results Transparency

0 of 10 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

10(66.7%)

Phase 3

2(13.3%)

N/A

2(13.3%)

Phase 1

1(6.7%)

15Total

Phase 4(10)

Phase 3(2)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT05715424Not ApplicableRecruiting

Community Intervention and Demonstration Area Construction

Role: collaborator

NCT04051736Phase 4Completed

Immunogenicity and Safety of Sabin-IPV Replacement Vaccination

Role: collaborator

NCT03235336Unknown

Associations Between Tea and Sweetened Beverage Consumptions and Hyperuricemia: The China Health and Nutrition Survey

Role: collaborator

NCT02133469Not ApplicableCompleted

PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae

Role: collaborator

NCT01821911Phase 4Completed

The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

Role: lead

NCT01827917Phase 4Completed

The Protection Effect of Speeda® Rabies Vaccine for Human Use

Role: lead

NCT02281396Phase 1Completed

The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans

Role: lead

NCT02288286Phase 3Completed

Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans

Role: lead

NCT01866566Phase 4Unknown

The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination

Role: lead

NCT01830283Phase 4Unknown

The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination

Role: lead

NCT01830257Phase 4Unknown

Explore Active Surveillance Mode of the Community's Adverse Event Following Immunization(AEFI)

Role: lead

NCT01758185Phase 4Completed

Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine

Role: lead

NCT01761136Phase 4Completed

The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection Site

Role: lead

NCT01654809Phase 4Completed

Safety and Immunogenicity Study of Split Influenza Virus Vaccine in Different Age Groups

Role: lead

NCT01684072Phase 4Completed

Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin

Role: lead

NCT01068015Phase 3Unknown

(Men Who Have Sex With Men) MSM Community Intervention Trial

Role: collaborator

All 16 trials loaded